Blog
RSS FeedPosted by Michael Wonder on 12 Mar 2019
Overview of cost-effectiveness analysis
11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...
Posted by Michael Wonder on 07 Mar 2019
Forget about an international pricing index for drugs. Cost-effectiveness is a better bargain
7 March 2019 - To make medicines more affordable, President Trump insists that “foreign freeloading” must end. ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 05 Mar 2019
Methodological problems in the method used by IQWiG within early benefit assessment of new pharmaceuticals in Germany
5 March 2019 - The decision matrix applied by the IQWiG for the quantification of added benefit within the early benefit ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 23 Feb 2019
When biotechs get breakthrough therapy status, Mr. Market yawns
23 February 2019 - As a biotech consultant, I’ve heard many CEO’s tell me that a “drumbeat of news” is ...
Posted by Michael Wonder on 21 Feb 2019
Linking cancer drug prices to treatment success could speed up approvals. But what do patients consider success?
21 February 2019 - The NHS spends more than £2 billion on cancer drugs each year in the UK. And ...
Posted by Michael Wonder on 14 Feb 2019
Determining value in health technology assessment: stay the course or tack away?
15 February 2019 - The economic evaluation of new health technologies to assess whether the value of the expected health benefits ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...
Posted by Michael Wonder on 07 Feb 2019
Cigna eclipses 50% in value-based care pay to providers
7 February 2019 - Cigna says it’s paying more than half of its reimbursements to medical care providers in its ...
Posted by Michael Wonder on 23 Jan 2019
Discrete choice experiments in health economics: past, present and future
23 January 2019 - Discrete choice experiments are increasingly advocated as a way to quantify preferences for health. ...
Posted by Michael Wonder on 23 Jan 2019
ICER launches international collaborative to develop new methods to guide value-based pricing of potential cures
23 January 2019 - NICE in the UK and CADTH in Canada among international agencies participating; public input on key methodological ...
Posted by Michael Wonder on 21 Jan 2019
Will price be a barrier to new cancer immunotherapy?
19 January 2019 - Advisory group CADTH recommends no funding for new CAR-T therapy until drug company lowers cost. ...
Posted by Michael Wonder on 17 Jan 2019
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
17 January 2019 - Public comments on draft protocol will be accepted through 13 February 2019. ...